#478 — The Psychedelic Mind

Field Experiences Growth in Research and Setbacks

Robin Carhart-Harris highlights the remarkable recent growth in psychedelic research. The publication rate and volume of psychedelic studies is higher than ever, with more high-quality, larger-scale clinical trials published yearly. In the last 20 years, there have been dozens of small trials and several influential, larger studies, such as phase 2b and phase 3 work by Compass Pathways. These larger trials enroll hundreds of patients across multiple sites, marking new scientific momentum in the field.

Despite this research boom, the psychedelic medicine industry has experienced market corrections. Valuations for companies in the sector soared—one reaching several billion dollars—but have since dropped dramatically. A primary catalyst for this decline was the FDA’s rejection of Lykos-Maps’s application for MDMA-assisted therapy for PTSD. Although there were valid concerns justifying the FDA’s caution, this regulatory setback created pessimism and contributed to the dramatic reduction in investor confidence and company valuations in the psychedelic medicine sector.

Psilocybin Therapy For Treatment-Resistant Depression Is the Leading Candidate For Approval, Though Regulatory Communication Remains Uncertain

Psilocybin therapy for treatment-resistant depression represents the most advanced and promising candidate for regulatory approval. Compass Pathways has progressed its psilocybin therapy program into phase three trials, enrolling hundreds of participants. Regulators, such as the FDA, have entertained the idea of “rolling submission,” allowing companies to submit partial data for early review, potentially speeding up the approval process. However, the regulatory outlook is mixed, with both optimistic and conflicting messages coming from authorities.

The FDA’s recent rejection of the MDMA application by Lykos-Maps was partly due to confusion regarding the agency’s mandate. The FDA is primarily charged with approving drugs rather than psychotherapy or combination treatments; the application’s emphasis on MDMA-assisted therapy created uncertainty as to whether the FDA had jurisdiction over such treatments. This regulatory ambiguity contributed significantly to the application’s failure.

Additionally, Lykos-Maps's vulnerability as a regulatory target stemmed from its non-academic profile and links to advocacy. Unlike traditional academic or industry-sponsored research groups, MAPS—the non-profit behind Lykos—has been seen more as an advocacy organization with a charismatic leader than as a body of objective scientists. This positioning made the organization susceptible to accusations of adv ...

Robin Carhart-Harris emphasizes that the effectiveness of psychedelic-assisted therapy depends not only on the pharmacological action of the psychedelic compound, but also on the therapeutic context in which it is administered. This combination complicates regulation and requires a nuanced, integrated approach to both drug action and psychological support.

Psychedelic Treatment Relies On Both Pharmacological Action and Therapeutic Context, Not Just the Compound

Carhart-Harris explains that psychedelics induce a state of heightened psychological plasticity. With this increased malleability, the mind becomes more shapeable, and the outcome of the treatment depends on how this plastic state is influenced. He states, “You have a plastic state. You’ve got to do the right thing with that. You know, it’s more shapeable, so shape it right. And so that’s where the context really, really matters.” The secret of effective psychedelic therapy is not just the drug, but the combination of the drug’s action and the context in which it is experienced. This integration of drug action and psychological support is unique to psychedelic medicine, making it fundamentally different from more conventional pharmacological treatments and more complex to regulate.

"Set and Setting" Dimensions Influencing Outcomes; Robin's Research on Elements Affecting Therapeutic Results

Carhart-Harris identifies “set” and “setting” as critical contextual dimensions that influence therapeutic outcomes. He defines “set” as the psychological preparation, mindset, expectations, beliefs, and readiness an individual brings into the session: “The mindset that you bring in, in a sense, the psychology that you bring in. Yes, expectations, but a lot more than that.” “Setting” refers to the immediate physical environment, including aesthetics, comfort, and sensory qualities: “the immediate environment for the experience.”

In ongoing research, Carhart-Harris’s lab isolates contextual variables to compare therapeutic benefits. The lab contrasts an “enriched condition," which includes supportive aesthetics and key elements of psychedelic-assisted therapy, with an “unenriched condition” that strips away these factors to test their additive value.

Staffing and Interpersonal Elements Shape Therapeutic Safety During Dosing of Vulnerable Psychological States

Carhart-Harris details that preparation is crucial: therapists help patients establish safety, clarify intentions, and cultivate an optimal mindset before dosing. During the dosing session, support is intentionally minimally directive and compassionate, with staff providing an indirect holding presence rather than traditional talk therapy. Carhart-Harris elaborates, "The support is typically quite hands-off, it's quite indirect, it's more like a holding rather than something directive. There's often quite little talking going on, so it's not traditional psychotherapy, it's not traditional talking therapy in the session itself." In the unenriched condition, staff are present primarily for safety monitoring, stepping in only during emergencies.

Integration sessions occur after the acute drug effects have worn off. Carhart-Harris notes, "it is in the prep and it is in what we call the integration, which is the therapy, the psychological support that comes after the dosing session. It might come the next day, it might come the next week, and plus maybe one or two sessions on top of that is how we tend to do it in the field."

Music as a Non-verbal Therapeutic Agent

Music plays a crucial role, serving as a “hidden therapist” during dosing because the session is so non-directive. Carhart-Harris and colleagues recognize that curated musical soundscapes deeply heighten emotional depth, making music choice central to therapy. He describes music as potentially overwhe ...

The quality of therapist training and ethical guidance in psychedelic-assisted psychotherapy is crucial to patient safety, particularly given the heightened vulnerability and suggestibility of patients in altered states. Facilitators must avoid imposing their own beliefs and navigate ambiguous memories with professionalism, focusing on healing while preventing harm.

Therapist Competence and Ethical Training Prevent Harm By Addressing Power Imbalances in Vulnerable Psychedelic States

Therapists Must Avoid Imposing Beliefs on Patients, as It May Shape Experiences, Leading To False Convictions and Psychological Harm

Sam Harris provides the example of a person under psychedelics, uncertain whether a recollection of childhood sexual abuse was a real memory or merely imagination. In this case, the therapist led the session with strong beliefs about the reality of recovered memories, telling the subject, "the body never lies or the body never forgets." This framing decisively shaped the subject's experience, making them believe the memory was real. Robin Carhart-Harris describes such practice as problematic, highlighting the harm caused when therapists transfer their assumptions onto vulnerable individuals in altered states. Cases like these have occurred in trials and major clinical sites.

Therapeutic Bias Can Transform Equivocality Into False Certainty

Initially, the subject was deeply uncertain about the authenticity of the memory, but the therapist's dogmatic stance transformed this uncertainty into a conviction that they had recovered an authentic traumatic memory—with the result being psychological harm. This illustrates how therapeutic bias can dangerously shift equivocal experiences into false certainties. Carhart-Harris emphasizes the importance of therapists listening compassionately and working with imagined or real content therapeutically, but without making a call on whether an alleged event happened.

Recovered Memory Risks in Psychedelic Sessions Echo Hypnotherapy Harms

Psychedelics Enhance Suggestibility and Diminish Critical Evaluation, Potentially Acting As "Hypnosis on Steroids" For Implanting or Reinforcing False Memories Through Subtle Therapeutic Cues

Harris remarks that psychedelics can act like "hypnosis on steroids," given their ability to enhance suggestibility and diminish critical thinking. He draws parallels to historic harms in hypnotherapy, where witnesses were induced to create false memories. In psychedelic states, a therapist’s suggestions or framing, even subtle, can implant or reinforce false memories due to increased vulnerability.

Psychedelic-Assisted Recovered Memories as Legal Evidence: A New Liability Vector

Harris expresses concern that if memories recovered under psychedelics are used as legal evidence, it could create new avenues for harm and liability, particularly if those memories are influenced therapeutically and later prove inaccurate or fabricated.

Distinguishing Genuine Early Memories From Imaginative Constructions In a Psychedelic State Is Challenging

Both Harris and Carhart-Harris note the difficulty in distinguishing authentic early memories from creative constructions during highly suggestible states. The problem is compounded when therapists, intentionally or unintentionally, guide or confirm ambiguous experiences.

Responding To Ambiguous Recovered Memories Requires Neutrality and Sophistication, Not Endorsement or Denial

Navigating Uncertain Trauma Memories In Therapy

Robin Carhart-Harris shares a case in which a patient wondered if one of his parents had tried to smother him as a child. The patient’s ambivalence and need for closure created clinical turbulence and a meaningful increase in symptom severity following a psilocybin session. Carhart-Harris emphasizes holding such ambiguous memories "very lightly," with therapists strictly avoiding endorsement or rejection, instead providing space and support as the patient works through uncertainty.

Robin's Case Involved a Patient Unsure if a Parent Tried to Smother Him, Causing Clinical Turbulence Requiring Extended Therapy, and Initially Worsened Mental Health Before Improving

This case highlights the hazards of ambiguous or uncertain trauma memories arising during psychedelic therapy. The patient was the only participant in a treatment-resistant depression trial to display a significant increase in symptoms post-treatment, requiring prolonged therapy and careful management.

Distinction Between Legally Documented Past Trauma (Appropriate for Present-Session Processing) Versus Unverified De Novo Trauma Claims From Psychedelic Experiences

C ...

Psychedelic Therapy: Most Benefit, Some Vulnerable Experience No Benefit or Worse

Across a range of mental health trials, Robin Carhart-Harris describes how the majority of results for psychedelic therapy are positive and consistent. Studies covering conditions such as depression, eating disorders, obsessive compulsive disorder, PTSD (including MDMA trials), anxiety, and addictions (alcohol, opiate, and cocaine) report highly reliable and replicated clinical benefits. The evidence base is broad, now spanning several dozen robust studies. These benefits consistently extend beyond simple symptom reduction. Carhart-Harris points to reliable improvements in well-being, life satisfaction, a sense of meaning, purpose, and psychological flourishing across both clinical and non-clinical populations. Survey data of individuals using psychedelics outside clinical trials—whether at music festivals, at home, or in supervised legal contexts—echo these findings: most report positive effects on well-being and self-concept.

Personality Disorders Predict Adverse Outcomes and Worsening Due to Emotional Volatility, Rigid Perception, Splitting, and Unstable Self-Concept

Despite this overall positive trend, Carhart-Harris emphasizes that not everyone benefits. People with a history of diagnosed personality disorder (PD) are at a markedly increased risk for adverse outcomes. Empirical data indicate those with such histories are four times more likely to fall into the worst outcome group following psychedelic use. PD is characterized by emotional volatility, histrionic or “splitty” presentations—where individuals perceive people and situations as entirely good or entirely bad—and unstable self-concept. This lack of nuance and rigidity in worldviews is particularly risky in the context of psychedelics.

Further detail reveals that while individuals with PD may show a slight initial improvement after psychedelic experiences, they typically deteriorate in the weeks that follow, demonstrating a clinically significant worsening of mental health. These findings derive from surveys of individuals using psychedelics in community settings, outside the rigors of clinical trials.

Psychotic Illness Is Contraindicated; Schizophrenia History Doubles Adverse Outcome Risk

Carhart-Harris identifies a clear contraindication for individuals with psychotic illnesses, such as schizophrenia. Those with such a history were twice as likely as others to experience the worst outcomes after psychedelic use. Borderline personality disorder is highlighted as a particularly concerning intersection of personality pathology and mild psychotic features—termed ‘borderline’ for its proximity to psychotic states. This group shows compromised reality testing and is especially vulnerable to psychedelic-induced decompensation.

For this reason, clinical trials universally exclude individuals with a history of psychotic illness, aiming to protect them from exacerbation of symptoms. This selection process creates a participant pool distinctly more resilient than the broader population of those with depression or other conditions. Such exclusion means that real-world risk to more vulnerable groups may not be apparent from trial result ...

MDMA vs. Psychedelics: Therapeutic Uses and Risks

Classic psychedelics such as LSD, psilocybin, ayahuasca, and DMT are described as "ego dissolvers" or "ego disintegrators" because they distort cognition and perception, producing transcendent or terrifying experiences. In contrast, MDMA creates only a subtle shift in perception, with a slight softening of the ego but without the profound disruption of reality seen with classic psychedelics. Reality testing and cognition remain comparatively intact with MDMA, minimizing the risk of extreme psychological states.

MDMA as a "Heart Opener" for Connection, Psychedelics as "Head Openers" Disrupting Cognition

MDMA is often described as a "heart opener," promoting relational and social exchange, making it easier for individuals to open up, express vulnerabilities, and communicate. This property allows for the possibility of conducting relatively conventional talk therapy during an MDMA session. In contrast, classic psychedelics function more as "head openers," profoundly disrupting standard cognition and making experiences unpredictable; thus, the therapeutic context and the skill of the guides become critical factors in treatment outcomes.

MDMA's Predictability and Independence Make It More Resilient Than Classic Psychedelics, With Personality Disorders and Psychosis Still Contraindications

MDMA generally induces positive emotional states regardless of the context, making it more predictable and resilient to environmental factors than classic psychedelics, which can lead to either euphoric or deeply distressing experiences depending on a multitude of variables. However, even though MDMA shows this pharmacological resilience, it does not entirely negate vulnerability factors. Individuals with personality pathology, severe emotional dysregulation, or a predisposition to psychosis may still be at risk, and specific contraindications may apply. These risks may not be identical to those associated with classic psychedelics but remain clinically relevant and need further clarification.

Robin Questions Whether the Same Co ...